What LTL Pharma does

LTL Pharma Co., Ltd. (LTLファーマ株式会社) is a Tokyo-headquartered pharmaceutical company established in August 2016 by private equity firm Unison Capital Group, with JPY 3.65 billion in registered capital and 60 employees. The company specializes exclusively in "Long-life Medicines" (ロングライフ医薬品) — prescription ethical drugs that have been on the market for decades — acquiring marketing authorizations from originator pharmaceutical companies and ensuring their uninterrupted stable supply to patients. Its portfolio spans antibiotics (Sawacillin, Cefzon, Cefamezin α), gastrointestinal drugs (Gaster), cardiovascular agents (Perdipine, Nivadil), central nervous system therapies (Seroquel, Emilace, Solantal), antiemetics (Nasea), dermatology (Nerisona), nephrology (Oxarol), and other specialty products, with assets sourced from Astellas, Sanofi, LEO Pharma, Chugai, and AstraZeneca.

LTL Pharma operates an asset-light business model: it holds no manufacturing facilities and outsources all production to Contract Manufacturing Organizations (CMOs), with double-sourcing of active pharmaceutical ingredients to mitigate supply risk. Quality assurance is partially outsourced to Contract Research Organizations (CROs). Distribution in Japan runs through a network of 38 specialty pharmaceutical wholesalers, with a minimal in-house Medical Representative (MR) force and a dedicated call center supporting healthcare professionals. The company added a digital touchpoint in January 2025 with the launch of the LTL Chatbot, an AI-powered text search service for product inquiries available 24/7 to medical professionals.

Internationally, LTL Pharma operates through local partners across 16 countries — seven in Asia (China, South Korea, Singapore, Thailand, Philippines, Indonesia, Pakistan), seven in Europe (Italy, Portugal, Germany, Spain, Slovenia, France, Finland), plus Iceland and Mexico — supplying APIs, bulk products, finished products, and trademarks. The company is privately held under Unison Capital Group, with no public listing, and Tetsuo Ito serves as President and Representative Director. The business model generates revenue primarily through one-time licensing and ongoing wholesale distribution of prescription drugs at Japan national insurance pricing, with a strategic M&A engine focused on acquiring additional marketing authorizations from originator companies divesting mature, non-core assets.

Name

LTL Pharma

Legal name

LTLファーマ株式会社

Website

https://ltl-pharma.com

Company type

Private

Founded year

2016

Operating status

Operating

Short description

LTL Pharma is a Tokyo-based, Unison Capital–backed pharmaceutical company that acquires marketing authorizations for long-listed prescription drugs from originator companies (Astellas, Sanofi, LEO Pharma, Chugai, AstraZeneca) and ensures their stable supply to healthcare professionals in Japan and 16 international markets through wholesalers and local partners.

Ownership category

akta.pro rank

Product category

Pharmaceuticals — Long-Listed Ethical Drugs (Off-Patent Prescription Medicines)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

akta.pro secondary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Long-listed ethical drugs
• Prescription pharmaceuticals
• Off-patent drug supply
• Marketing authorization transfer
• Specialty pharmaceutical distribution

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Ethical Drug Sales: Manufacturing, marketing and import/export of prescription ethical drugs (医療用医薬品). Revenue is generated through sales of long-listed pharmaceutical products (長期収載品) acquired from originator companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

LTL Pharma is a Japanese pharmaceutical company that acquires manufacturing and marketing authorizations for long-listed ethical drugs (ロングライフ医薬品) from originator pharmaceutical companies and ensures their stable, uninterrupted supply to healthcare professionals and patients in Japan and 16 international markets. The company operates without in-house manufacturing, outsourcing production to Contract Manufacturing Organizations (CMOs) and distributing through specialty pharmaceutical wholesalers. It also offers an AI-powered chatbot (LTLチャットボット) for 24/7 medical-professional inquiries about its drug portfolio.

Product overview

LTL Pharma is a Japanese pharmaceutical company specializing in long-listed ethical drugs (ロングライフ医薬品/長期収載品) - prescription drugs that have been on the market for many years with established safety and efficacy profiles. The company operates through a unique business model of acquiring marketing authorizations from originator companies and ensuring stable supply of these products to patients. The product portfolio spans multiple therapeutic areas including antibiotics (Sawacillin/amoxicillin, Cefzon/cefdinir, Cefamezin α/cefazolin), cardiovascular drugs (Perdipine/nicardipine, Gaster/famotidine), central nervous system medications (Seroquel/quetiapine, Emilace/setiptiline, Solantal/talipexole, Hypoca/bamifylline, Logan/Rodopin/rotigotine), antiemetics (Nasea/ramosetron), vitamins (Neurovitan combination tablets), and specialty products (Oxarol/maxacalcitol for secondary hyperparathyroidism, Spongel hemostatic agent). Products are distributed through authorized pharmaceutical wholesalers across Japan and internationally through local partners in 16 countries. The company also provides an AI-powered chatbot service (LTLチャットボット) for medical professional inquiries. LTL Pharma outsources all manufacturing to CMOs and does not own in-house production facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Gaster (ガスター) — famotidine H2 receptor antagonist H2 receptor antagonist (famotidine) for gastric/duodenal ulcers, reflux esophagitis, and upper gastrointestinal bleeding, available in tablets, orally disintegrating (D) tablets, powder, and injection; prescribed by healthcare professionals.
• Sawacillin (サワシリンナ) — amoxicillin hydrate penicillin antibiotic Synthetic penicillin antibiotic (amoxicillin hydrate) effective against gram-positive and gram-negative bacteria; used for various infections and H. pylori eradication therapy in capsules, fine granules, and tablets.
• Cefzon (セフゾン) — cefdinir oral cephalosporin antibiotic Oral cephalosporin antibiotic (cefdinir) effective against methicillin-sensitive Staphylococcus, Streptococcus, Pneumococcus, Haemophilus influenzae, and other pathogens; available in capsules and pediatric fine granules.
• Perdipine (ペルジピン) — nicardipine hydrochloride calcium channel blocker Calcium channel blocker (nicardipine hydrochloride) for essential hypertension, surgical procedural hypertension, hypertensive emergencies, and acute heart failure; available in tablets, sustained-release (LA) capsules, powder, and injection.
• Cefamezin α (セファメジンα) — cefazolin sodium hydrate cephalosporin antibiotic Japan's first domestically developed cephalosporin antibiotic (cefazolin sodium hydrate) for treating various bacterial infections; available in intramuscular injection, injection, and drip infusion kit formulations.
• Oxarol Injection (オキサロールド注) — maxacalcitol vitamin D3 derivative Vitamin D3 derivative (maxacalcitol) injection for treating secondary hyperparathyroidism in maintenance dialysis patients with chronic kidney disease; available in 2.5μg, 5μg, and 10μg intravenous formulations.
• Seroquel (セロクエル) — quetiapine fumarate atypical antipsychotic Atypical antipsychotic (quetiapine fumarate) for treating schizophrenia; available in 25mg, 100mg, 200mg tablets and 50% fine granules.
• Emilace (エミレース) — setiptiline maleate antidepressant Antidepressant (setiptiline maleate) in 3mg and 10mg tablet formulations.
• Solantal (ソランダール) — talipexole dopamine agonist Dopamine agonist (talipexole) for treating Parkinson's disease and related conditions; available in 50mg and 100mg tablets.
• Dellegra Combination Tablets (ディレグラ配合錠) — pseudoephedrine + guaifenesin combination Combination tablet of pseudoephedrine and guaifenesin for treating nasal congestion and cough associated with the common cold.
• Nasea (ナゼア) — ramosetron hydrochloride 5-HT3 antiemetic 5-HT3 receptor antagonist antiemetic (ramosetron hydrochloride) for treating nausea and vomiting; available in orally disintegrating (OD) tablets and injection.
• Nivadil (ニバジール) — nilvadipine calcium channel blocker Calcium channel blocker (nilvadipine) for hypertension; available in 2mg and 4mg tablets.
• Neurovitan Combination Tablets (ノイロビタン配合錠) — vitamin B complex Vitamin B complex combination preparation for nutritional supplementation.
• Hypoca (ハイポカ) — bamifylline hydrochloride bronchodilator Xanthine-derivative bronchodilator (bamifylline hydrochloride) for bronchial asthma and related conditions; available in 5mg, 10mg, and 15mg capsules.
• Logan (ロヘン) — rotigotine dopamine agonist tablet Dopamine agonist (rotigotine) tablet for Parkinson's disease; available in 10mg tablets.
• Rodopin (ロドピン) — rotigotine dopamine agonist patch Dopamine agonist patch (rotigotine) treatment for Parkinson's disease; available in 10% and 50% fine granules, and 25mg, 50mg, and 100mg tablets.
• Spongel (スポンゼール) — gelatin sponge hemostatic agent Gelatin sponge hemostatic agent for hemostasis during surgical procedures; available in 2.5cm×5cm and 7cm×10cm sizes.
• Nerisona (ネリゾナ) — clocortolone pivalate topical corticosteroid Topical corticosteroid (clocortolone pivalate) for treating inflammatory skin conditions, transferred from LEO Pharma K.K.; available in cream, ointment, universal cream, and solution formulations.
• LTLチャットボット (LTL Chatbot) — AI search service for medical professionals AI-powered 24/7 text-based chatbot providing automated answers to frequently asked questions about LTL Pharma's pharmaceutical products, available free of charge to medical professionals through the company website.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Sanofi K.K.coreStrategic or Co-development Partner · 1 August 2020Acquired manufacturing/marketing authorization for 1 anti-allergic agent product from Sanofi K.K.
• Astellas Pharma Inc.coreStrategic or Co-development Partner · 1 August 2016LTL Pharma's founding partnership - acquired 16 ethical drug products including H2 receptor antagonist, antibiotics (5 products), 5-HT3 receptor antagonist antiemetic, anti-hypertensive drugs (4 products), schizophrenia treatment drugs (2 products), mixed vitamin preparation, gelatin sponge for hemostasis, and analgesic/anti-inflammatory agent. This transfer marked LTL Pharma's establishment.
• LEO Pharma K.K.coreStrategic or Co-development PartnerTransferred distribution rights for 2 products: topical corticosteroid and anti-hemorrhoidal agent.
• CRO Partners (Contract Research Organizations)minorStrategic or Co-development PartnerOutsourcing practical work to CROs for quality assurance operations, allowing in-house personnel to focus on planning and management of quality assurance matters in Japan and overseas.
• CMO Partners (Contract Manufacturing Organizations)coreStrategic or Co-development PartnerLTL Pharma does not own in-house manufacturing facilities and entrusts production of all products to CMOs. Works on double-sourcing of active pharmaceutical ingredients and maintenance of production equipment.
• Local Partners in Asia (7 countries)minorChannel Partner/ Reseller/ DistributorOverseas partnerships in China, South Korea, Singapore, Thailand, Philippines, Indonesia, and Pakistan for supply of active pharmaceutical ingredients, bulk products, final products, and trademark licensing.
• Local Partners in Europe (7 countries)minorChannel Partner/ Reseller/ DistributorOverseas partnerships in Italy, Portugal, Germany, Spain, Slovenia, France, and Finland for supply of active pharmaceutical ingredients, bulk products, final products, and trademark licensing.
• Local Partners in Other Regions (Iceland, Mexico)minorChannel Partner/ Reseller/ DistributorOverseas partnerships in Iceland and Mexico for supply of active pharmaceutical ingredients, bulk products, final products, and trademark licensing.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Astellas Pharma: Major Japanese originator pharmaceutical company that was the founding product source for LTL Pharma (16 products in 2016-2019). Comparable as a Japanese pharma counterpart whose product-divestment activities directly shaped LTL's portfolio, though Astellas remains a much larger R&D-focused innovator.
• Sanofi K.K. (Japan): Japanese subsidiary of global originator Sanofi, which transferred marketing authorization of anti-allergic and Seroquel products to LTL Pharma. Comparable as a Japanese pharma operations counterpart with a long-listed product portfolio, and a continued source of potential divestments to LTL.
• Kyowa Kirin: Japanese specialty pharmaceutical company with a presence in both innovative biologics and older established products. Comparable as a Japanese pharma with a portfolio straddling established and innovative segments, and a potential product-divestment counterpart for LTL's acquisition pipeline.
• Chugai Pharmaceutical: Major Japanese originator pharmaceutical company (Roche group) that has divested mature products to LTL Pharma (e.g., Oxarol injection in 2024). Comparable as a Japanese pharma counterpart doing originator-to-specialist product transfers, though operating at much greater scale with a focus on innovative biologics.

Direct peers

• Fuji Pharma: Japanese specialty/generic pharmaceutical company focused on women's health and acute care products. Comparable to LTL Pharma as a Tokyo-based specialty pharma operating in the Japanese off-patent prescription drug market with similar scale.
• Towa Pharmaceutical: Japanese generic pharmaceutical manufacturer specializing in off-patent oral solids, injections, and other dosage forms. A direct competitor to LTL Pharma in the Japanese long-listed/generic prescription drug market with comparable product portfolio philosophy and scale.
• Nichi-Iko Pharmaceutical: Major Japanese generic pharmaceutical manufacturer and one of the largest domestic producers. Closely comparable to LTL as a Japanese specialty/generic pharma pursuing off-patent and established brands, with similar distribution through wholesalers and an analogous regulatory-authorization-driven business model.
• Aska Pharmaceutical: Japanese specialty pharmaceutical company with a portfolio spanning generics and long-listed products in specific therapeutic areas. Comparable to LTL Pharma as a mid-sized Japanese pharma operating with an originator-succession business model in the domestic market.
• Sawai Group Holdings: One of Japan's largest generic pharmaceutical companies, listed on the Tokyo Stock Exchange. Directly comparable as a Japanese generic pharma competing in the same off-patent/long-listed product categories that LTL Pharma targets, with overlapping distribution channels and target customer base.
• Daiichi Sankyo Espha: Generic pharmaceutical subsidiary of Daiichi Sankyo, one of Japan's largest originators. Direct competitor to LTL Pharma in the Japanese long-listed/generic segment, leveraging parental originator pipelines for product transfers in the same way LTL capitalizes on its Astellas/Sanofi origin.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LTL Pharma